Honasa Consumer Limited terminated its proposed acquisition of a 58% equity stake in Fluence Pharma Private Limited. The cancellation was announced on August 25, 2026, citing the non-fulfilment of closing conditions specified in the Share Purchase Agreement.

The disclosure follows an earlier notification dated June 23, 2026, which had outlined the proposed acquisition subject to the completion of specific conditions precedent.

Regulatory Disclosure

The update was filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed both the National Stock Exchange of India Limited and BSE Limited regarding the termination of the transaction.

Strategic Outlook

Honasa stated it remains committed to its nutraceutical strategy. The company indicated it will continue to evaluate organic and inorganic opportunities to build a consumer-focused business in this category.

Transaction Details

The disclosure was signed by Gaurav Pandit, Company Secretary and Compliance Officer, on behalf of Honasa Consumer Limited.

Honasa Consumer Limited delivered its highest-ever quarterly revenue and profit in the first quarter of fiscal year 2027 (Q1FY27), signaling robust momentum across its digital-first beauty and personal care portfolio. The company, known for brands like mamaearth , The Derma Co., and BTM Ventures, reported a 31.8% year-on-year revenue growth, reaching a record ₹785 crore on a like-for-like (LFL) basis. This top-line expansion was accompanied by significant margin improvement, with EBITDA more than doubling to ₹110 crore.

The Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, during a meeting held on August 13, 2026. In compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company notified the stock exchanges of the approval. Chairman, CEO and Whole Time Director Varun Alagh signed off on the results.

The financial results were published in the English edition of the Financial Express (All India editions) and the Hindi newspaper Jansatta (Delhi edition) on August 14, 2026. Company Secretary and Compliance Officer Gaurav Pandit confirmed the publication and noted that the disclosure is also hosted on the company’s website.

The financial results highlight a broad-based acceleration across the company’s "House of Brands" strategy. Net profit after tax (PAT) reached an all-time high of ₹90 crore, translating to a PAT margin of 11.5%. The EBITDA margin expanded to 14.1%, up from 7.7% in the prior year period, indicating that the revenue growth is being converted into operating leverage rather than just volume gains.

Brand and Category Performance

The growth was not confined to a single brand but was distributed across core and younger portfolios. Mamaearth accelerated to high-teens growth, driven by its focus categories. Key products such as Rice Dewy Bright Face Wash and Rosemary Anti-Hair Fall Shampoo emerged as primary growth drivers, with Rice Dewy Bright becoming the company’s number one face cleanser. Brand searches for Mamaearth grew 36% year-on-year in Q1FY27.

The Derma Co. crossed the ₹1,000 crore net sales value (NSV) annual recurring revenue (ARR) mark and entered the "teens EBITDA club," making Honasa the only FMCG company in India to build two ₹1,000 crore brands in the last decade. Face cleansers within this brand crossed ₹200 crore ARR. Meanwhile, younger brands grew at over 40%, with traction in Gen Z innovation, premium serums, men’s skincare, hair color, and sunscreen segments.

BTM Ventures, acquired by Honasa, crossed ₹150 crore ARR, growing more than 2x since acquisition. The brand is expanding beyond its South India stronghold into Maharashtra and newer channels, diversifying the company’s geographic and channel risk.

Channel Expansion and New Categories

Offline distribution saw substantial scaling, with both General Trade and Modern Trade growing by over 40%. Outlet coverage has crossed approximately 3 lakh FMCG retail outlets, reinforcing the company’s omnichannel strategy. Focus categories, which include high-growth product lines, grew by more than 35%, driven by strength across key channels. Their contribution to revenue expanded by 450 basis points year-on-year to over 85% in Q1FY27.

Honasa also entered the fragrance category with FIKN, India’s first elixir brand. This move targets a large, underpenetrated category in India, aiming to build a differentiated proposition beyond skincare and haircare. The company emphasized disciplined capital allocation and talent density as it pursues this new category entry.

Financial Highlights

A change in settlement by the Flipkart group impacted revenue recognition for Honasa, resulting in a ~₹29 crore impact on the topline with no effect on absolute profitability or contribution margin. Underlying volume growth stood at 30.5%, confirming that the expansion is volume-led. Cash generation reached ₹83 crore, supported by a negative working capital cycle.

What the Numbers Show

The divergence between revenue growth (31.8%) and EBITDA growth (140.7%) underscores significant operating leverage. The margin expansion from 7.7% to 14.1% was driven primarily by mix impact (+300-350 bps), leverage and seasonality (+100-150 bps), and non-recurring items (+150 bps, largely ESOP reversal). This indicates that profitability is scaling disproportionately to top-line growth, a positive signal for unit economics.